You are here

Agency Actions

Prevention, screening, treatment, and creative financing for medication sought
Days may be numbered for controversial payment initiatives
Agency finds fault with manufacturing facility
Agency needs more time to evaluate synthetic peptide
Inotuzumab ozogamicin moves to the head of the line
Company abused government processes to delay generic competition, agency contends
Phase 3 trial examines one-time angiogenic treatment
Decision based on positive phase 2 data